Pediatric Hematology/Oncology

DLBCL

Questions discussed in this category

What are your top takeaways in Lymphoma from ASH 2025?

3 Answers available

Papers discussed in this category

Lancet (London, England), 2025 Dec 07

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Lancet (London, England), 2025 Dec 05

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

The New England journal of medicine, 2025 Dec 06

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Related Topics in Pediatric Hematology/Oncology